<DOC>
	<DOCNO>NCT00559858</DOCNO>
	<brief_summary>RATIONALE : Pyridoxine ( vitamin B6 ) may prevent lessen hand-foot syndrome cause chemotherapy . It yet know whether pyridoxine effective placebo prevent hand-foot syndrome . PURPOSE : This phase III randomize trial study pyridoxine see well work compare placebo prevent hand-foot syndrome patient receive capecitabine advance colorectal cancer breast cancer .</brief_summary>
	<brief_title>Pyridoxine Preventing Hand-Foot Syndrome Patients Who Are Receiving Capecitabine Advanced Colorectal Cancer Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether pyridoxine reduce incidence capecitabine dose modification ( dose delay dose reduction ) due toxicity . Secondary - Determine incidence hand-foot syndrome ( HFS ) . - Determine overall toxicity . - Determine quality life . - Determine response chemotherapy . - Determine progression-free survival . - Determine level biomarkers might predict occurrence HFS . OUTLINE : This multicenter study . Patients stratify accord disease ( breast cancer v colorectal cancer ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral pyridoxine hydrochloride 3 time daily begin initiation capecitabine chemotherapy continue completion chemotherapy . - Arm II : Patients receive oral placebo 3 time daily begin initiation capecitabine chemotherapy continue completion chemotherapy . In arm , treatment continue absence disease progression unacceptable toxicity . Evidence hand-foot syndrome assess baseline course capecitabine . Quality life assess baseline every 6 week . After completion study treatment , patient follow 6 12 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance colorectal breast carcinoma Hormone receptor status specify Receiving singleagent capecitabine chemotherapy Measurable disease response assessment , determine individual patient basis , use conventional clinical and/or radiological method PATIENT CHARACTERISTICS : ECOG performance status 02 Menopausal status specify Life expectancy ≥ 12 week Hemoglobin ≥ 10 g/dL Platelet count ≥ 100,000 mm^3 WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Bilirubin ≤ 1.3 x upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 x ULN AST ALT ≤ 5 x ULN Creatinine ≤ 1.5 x ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No serious uncontrolled illness , opinion investigator , make undesirable patient enter trial No medical psychiatric condition would influence ability provide inform consent PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 6 week since prior investigational agent Concurrent radiotherapy allow No concurrent chemotherapy immunotherapy No concurrent nonsteroidal antiinflammatory drug NSAIDs ) primary purpose treat handfoot syndrome ( HFS ) cancer NSAIDs condition HFS cancer allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>palmar-plantar erythrodysesthesia</keyword>
	<keyword>breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>